Thursday, November 26, 2015

FDA warns of risk from certain asthma drugs

The U.S. Food and Drug Administration today warned against the use of certain asthma drugs without other medications because of concerns that so-called long-acting beta agonists could exacerbate patients' asthma and result in hospitalization or even death.

FDA warns of risk from certain asthma drugs


The U.S. Food and Drug Administration today warned against the use of certain asthma drugs without other medications because of concerns that so-called long-acting beta agonists could exacerbate patients' asthma and result in hospitalization or even death.

The FDA said long-acting beta agonists, or LABAs, “should never be used alone in the treatment of asthma in children or adults.”

Moreover the agency said, “when LABAs are needed, they be used for the shortest time possible to achieve asthma control.”

The FDA said it took the action based on its analysis of studies that showed use of the drugs such as Advair, Brovana, Foradil, Perforomist, Serevent, and Symbicort increased the risk of worsening asthma symptoms that could lead to hospitalization, and in some cases death.

LABAs relax the muscles of airways to allow easier breathing when taken using an inhaler or nebulizer.

“Although these medicines play an important role in helping some patients control asthma symptoms, our review of the available clinical trials determined that their use should be limited, whenever possible, due to an increased risk of serious asthma exacerbations and death,” says Badrul Chowdhury, M.D., director of FDA's Division of Pulmonary and Allergy Products.

We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy: comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
comments powered by Disqus
About this blog

Check Up is a blog for savvy health consumers, covering the latest developments, discoveries, and debates from the Philadelphia area and beyond.

Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Charlotte Sutton Health and Science Editor, Philadelphia Inquirer
Tom Avril Inquirer Staff Writer, heart health and general science
Stacey Burling Inquirer Staff Writer, neuroscience and aging
Marie McCullough Inquirer Staff Writer, cancer and women's health
Don Sapatkin Inquirer Staff Writer, public health, infectious diseases and substance abuse
Justin D'Ancona
David Becker, M.D. Board certified cardiologist, Chestnut Hill Temple Cardiology
Michael R. Cohen, R.Ph. President, Institute for Safe Medication Practices
Daniel R. Hoffman, Ph.D. President, Pharmaceutical Business Research Associates
Hooman Noorchashm, M.D., Ph.D. Cardiothoracic surgeon in the Philadelphia area
Amy J. Reed, M.D., Ph.D. Anesthesiologist and Surgical Intensivist in the Philadelphia Area
Latest Health Videos
Also on
letter icon Newsletter